This is a clone of the Texas Administrative Code (TAC) for educational purposes. It is not the official version and should not be used for legal purposes. Site created Wed, 21 May 2025 21:16:42 GMT

TITLE 22 - EXAMINING BOARDS
PART 9 - TEXAS MEDICAL BOARD
CHAPTER 170 - STANDARDS FOR USE OF INVESTIGATIONAL AGENTS
SUBCHAPTER B - INVESTIGATIONAL STEM CELL TREATMENTS FOR PATIENTS WITH CERTAIN SEVERE CHRONIC DISEASES OR TERMINAL ILLNESSES
SECTION/RULE §170.5 - General Standards for the Use of Investigational Stem Cell Treatments for Patients with Certain Severe Chronic Diseases or Terminal Illnesses
Chapter Review Date 02/25/2008

In accordance with Chapter 1003 of the Texas Health and Safety Code, physicians who administer or provide for the use of investigational stem cell treatments must:(1) comply with all applicable state and federal laws and rules;(2) be certified to administer stem cell in accordance with §1003.055 of the Texas Health and Safety Code;(3) ensure the patient is enrolled in a clinical trial investigating the use of adult stem cells in humans;(4) maintain adequate medical records including documentation of the patient's qualifying severe chronic disease or terminal illness;(5) obtain a signed written informed consent including the patient eligibility determination found in §1003.053(2)(a) of the Texas Health and Safety Code; and(6) provide stem cells in a qualifying facility.

Source Note: The provisions of this §170.5 adopted to be effective January 9, 2025, 50 TexReg 349.

View Official Rule